Objectives: To evaluate the plasma trough concentrations (C trough ) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed.
Introduction
The availability of direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) gave the possibility to achieve high rates of sustained virological response (>90%) together with good tolerability profiles even in the so-called difficult-to-treat populations (e.g. null responder, compensated and decompensated cirrhotic patients). 1, 2 Offering the appropriate antiviral treatment to patients with CHC requires careful assessment of potential drug-drug interactions (DDIs), especially in HIV/hepatitis C virus (HCV)-coinfected patients, who cannot discontinue ART and, due to the long duration of HIV infection and ART exposure, may have few treatment options. Finally, very few data are available concerning the pharmacokinetics of concomitant ARV and DAAs in liver cirrhosis.
Given these considerations, we investigated the pharmacokinetics of an antiretroviral regimen with dolutegravir plus rilpivirine, for which a lack of significant DDIs has been demonstrated in healthy adults, 3 with or without NRTIs and of concomitant anti-HCV treatment with simeprevir plus sofosbuvir with or without ribavirin in ART-experienced patients with liver cirrhosis.
Methods
A prospective observational study in adult patients infected with HCV (genotype 1 or 4) and HIV-1 affected by liver cirrhosis (defined as liver stiffness >12.5 kPa and/or clinical or ultrasonographic signs of liver cirrhosis), with plasma HIV-RNA <50 copies/mL at the start of anti-HCV therapy, on ART with dolutegravir plus rilpivirine with or without NRTIs V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
and treated with simeprevir plus sofosbuvir with or without ribavirin for 12 weeks, was conducted. Ribavirin was added to the anti-HCV regimen in absence of contraindicating conditions (e.g. severe cardiac disease, severe pre-existing anaemia or previous severe intolerance). Treatment follow-up was performed as recommended by the current guidelines from the European Society for the Study of Liver Diseases (EASL), 2 with evaluations at DAA baseline (BL), on-treatment weeks 4 and 12/end of treatment (EOT) and at post-treatment (PT) weeks 4 and 12. Further assessment for biochemical toxicities was performed at week 2. Plasma HCV-RNA and HIV-RNA were determined using Abbott Molecular RealTime PCR.
Plasma samples were collected before the administration of the next dose of ART and DAAs. Trough concentrations (C trough ) of dolutegravir (50 mg once daily), rilpivirine (25 mg once daily), sofosbuvir (400 mg once daily, measured as the active metabolite GS-331007) and simeprevir (150 mg once daily) were evaluated with a validated HPLC method 4 at BL (only dolutegravir and rilpivirine) and on-treatment weeks 2 and 4.
No formal sample size calculation was performed a priori for this study; any eligible subject who underwent pharmacokinetic sampling at the scheduled timepoints was considered in this study.
Patient characteristics were described as median (IQR) or n (%), as appropriate. Geometric means were calculated to summarize C trough values. Linear mixed-effect models were fitted to log 10 -transformed C trough to assess changes over the first 4 weeks. From these models after backtransformation, 95% CIs around the geometric mean of C trough of dolutegravir, rilpivirine, sofosbuvir and simeprevir were computed.
The statistical analysis was performed using SAS software, release 9.2 (SAS Institute).
Ethics
The study was approved by the Ethics Committees of the centres involved. Written informed consent was obtained from the participants.
Results
Twelve patients were evaluated. Their main demographic, clinical and virological characteristics are described in Table 1 .
Geometric means (95% CI) of rilpivirine and dolutegravir at DAA BL, week 2 and week 4 and the corresponding untimed mean values (overall) are described in Figure 1 (a) and Figure 1(b) , respectively. No significant changes were observed during the first 4 weeks in dolutegravir (P ¼ 0.268) and rilpivirine C trough (P ¼ 0.654).
Geometric means (95% CI) of GS-331007 and simeprevir at ontreatment weeks 2 and 4 and corresponding overall values are described in Figure 1 (c) and Figure 1(d) , respectively. The C trough of GS-331007 and simeprevir did not vary between weeks 2 and 4 (P ¼ 0.643 and P ¼ 0.179, respectively).
All patients completed the full course of anti-HCV treatment. No serious adverse events were observed. At on-treatment week 4, 67% of patients had plasma HCV-RNA <12 IU/mL, while all the patients achieved EOT virological response, which was maintained up to PT week 12 (sustained virological response). Regarding HIV virological control, 10/12 (83%) patients maintained suppressed HIV-RNA (<50 copies/mL) up to PT week 24. One patient (ID 09) experienced HIV virological breakthrough at the end of anti-HCV therapy due to non-compliance with ART: plasma HIV-RNA was 20906 copies/mL with undetectable drug plasma levels at the EOT visit, while undetectable HIV-RNA was recorded at BL, week 2 and week 4 with rilpivirine and dolutegravir C trough of 151 and 1520 ng/mL, 144 and 1530 ng/mL and 72 and 1094 ng/mL, respectively. Another patient (ID 05) experienced virological failure: plasma HIV-RNA was undetectable at BL with rilpivirine and dolutegravir C trough of 231 and 1173 ng/mL, while HIV-RNA was 152 and 191 copies/mL at weeks 2 and 4, respectively, with rilpivirine and dolutegravir C trough of 198 and 2199 ng/mL and of 162 and 1313 ng/mL at weeks 2 and 4, respectively. In both cases, genotypic resistance testing was performed, but no mutations for NRTIs, NNRTIs, PIs and integrase inhibitors were detected. After exclusion of the patient non-compliant with ART, 10/11 (91%) maintained HIV virological suppression for the considered time period.
A slight reduction in the CD4 cell absolute count was recorded during anti-HCV treatment [change BL-EOT: À92 (IQR À143 to þ 39) cells/mm 
Discussion
In this small study, the geometric means of dolutegravir and rilpivirine plasma trough levels appeared not to be affected by concomitant simeprevir and sofosbuvir administration in patients with liver cirrhosis. To our knowledge, this is the first report in the literature evaluating the pharmacokinetics of dolutegravir/rilpivirineincluding antiretroviral regimens in patients treated with sofosbuvir plus simeprevir for CHC.
The trough concentrations observed in these patients are in line with those previously reported in healthy volunteers and in HIVmonoinfected or HCV-monoinfected subjects, even though their mean values tend to be higher. In a study including healthy volunteers (N ¼ 12), the rilpivirine mean trough concentration was 67 6 30 ng/mL, 5 while an overall geometric mean of 135 (95% CI 102-177) ng/mL was observed in our study. Differently from a Pharmacokinetics in liver cirrhosis JAC previous study in healthy volunteers, which reported a 25% increase in rilpivirine trough concentrations with simeprevir, 6,7 a 13% increase in the rilpivirine trough concentrations after starting simeprevir was observed, not achieving statistical significance. The mean trough concentration of dolutegravir was 1100 (5th-95th percentiles 532-2240) ng/mL in population pharmacokinetic analysis using data from the SPRING-1 and SPRING-2 clinical trials, 8 while an overall geometric mean of 1357 (95% CI 970-1897) ng/mL was obtained in our study. Concerning DAAs, the simeprevir trough concentration was 2357 (95% CI 1569-4101) ng/mL in our sample compared with 1936 6 2640 (geometric mean 6 standard deviation) ng/mL in HCV-infected patients enrolled in Phase III studies, 9 1431 6 1501 ng/mL in HCV-infected patients with Child-Pugh stage A liver cirrhosis and 1637 6 1191 and 5568 6 3519 ng/mL in HCVnegative subjects with moderate and severe hepatic impairment, respectively. 10 A lower trough value of simeprevir was observed at week 4 compared with week 2, even though this variation is not statistically significant; although the reason for this change is not clear, it may be possibly attributed to an increased liver metabolism or elimination promoted by the drug itself.
The tendency to higher trough values of antiviral drugs in these patients may be attributed to a reduced liver function, responsible for slower drug metabolism. 11 Previous studies showed a progressive reduction in the expression of liver cytochromes P450 together with impairment of liver function, especially regarding CYP2A19, which may be partly responsible for the metabolism of rilpivirine and simeprevir, and CYP3A, which plays a major role in rilpivirine and simeprevir metabolism. 5, 9 The expression of drug transporters may also be impaired in liver disease. 12 Moreover, oral drug bioavailability has been shown to be increased in chronic liver disease due to reduced pre-systemic drug metabolism because of intraand extrahepatic shunts.
11
Regarding HIV virological efficacy, our results are consistent with previous studies investigating the combination of dolutegravir or cabotegravir with rilpivirine. 13, 14 No resistance-associated variants were detected in the two patients experiencing virological failure.
Our study has some limitations. First, the suggestion of no potential DDIs among the study antiviral drugs may not be considered as a firm conclusion given the small sample size and the consequent low statistical power of detecting changes in trough concentrations that do not exceed 55% at best (in the case of simeprevir). Second, in this study only patients with liver cirrhosis are included, so the results cannot be generalized to the HIV/HCVcoinfected population. Moreover, only trough concentrations are available: the patients were instructed to take the daily dose after sample collection and the time since the last dose was selfreported. Moreover, patients were instructed to take their pills on a full stomach as simeprevir and sofosbuvir absorption is enhanced by food, but only the first dose of the treatment course was supervised. All patients reported compliance with dosing recommendations and the drug levels observed do not appear to be lower than expected.
Overall, despite a tendency to higher trough concentrations of both antiretrovirals and DAAs, our data on dolutegravir/rilpivirinebased ART during concomitant simeprevir plus sofosbuvir therapy showed that co-administration appears to be safe in HIV/HCVcoinfected patients with liver cirrhosis, even though further studies are warranted to fully assess DDIs with other drugs and potential toxicities in a larger sample of patients.
